Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medical Ikkou Group CoTSE:3353 -0.35%64 Debt-to-EBITDA is 3.49 as of Feb. 2026, which is 21% below its 10-year median of 4.42. GuruFocus rates TSE:3353 with a GF Score™ of 64/100 and a GF Value™ of 円3,589.36 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 453 Conglomerates companies, Medical Ikkou Group Co ranks worse than 60.04% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medical Ikkou Group Co's Debt-to-EBITDA or its related term are showing as below:
TSE:3353'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.49 Med: 4.42 Max: 5.34
Current: 3.49
During the past 13 years, the highest Debt-to-EBITDA Ratio of Medical Ikkou Group Co was 5.34. The lowest was 3.49. And the median was 4.42.
TSE:3353's Debt-to-EBITDA is ranked worse than 60.04% of 453
companies
in the Conglomerates industry
Industry Median: 2.71
vs TSE:3353: 3.49
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medical Ikkou Group Co Debt-to-EBITDA Related Terms
Medical Ikkou Group Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Medical Ikkou Group Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, Medical Ikkou Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Ikkou Group Co Debt-to-EBITDA vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Medical Ikkou Group Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medical Ikkou Group Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Feb. 2026) EBITDA data.
Medical Ikkou Group Co (TSE:3353) has a Debt-to-EBITDA of 3.49 as of Feb. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medical Ikkou Group Co. This is 21% below median its historical median of 4.42. Over the past decade, Medical Ikkou Group Co's Debt-to-EBITDA has ranged from 3.49 to 5.34. According to the industry distribution chart, Medical Ikkou Group Co ranks #272 out of 453 companies in the Conglomerates industry, placing it in the top 60%.
Is Medical Ikkou Group Co's Debt-to-EBITDA too high?
Medical Ikkou Group Co's current Debt-to-EBITDA of 3.49 is 21% below median its 10-year median of 4.42. Over the past 10 years, this metric has ranged from a low of 3.49 to a high of 5.34. The Conglomerates industry median Debt-to-EBITDA is 2.71. Medical Ikkou Group Co's value of 3.49 is 28.8% above this industry median. Based on the distribution chart, Medical Ikkou Group Co ranks #272 out of 453 companies in the Conglomerates industry, which is below the industry midpoint. Overall, Medical Ikkou Group Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Ikkou Group Co's Debt-to-EBITDA compare to MMM and HON?
According to the Conglomerates industry distribution chart, Medical Ikkou Group Co ranks #272 out of 453 companies for Debt-to-EBITDA. This places Medical Ikkou Group Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.71. Medical Ikkou Group Co's value of 3.49 is 28.8% above this benchmark. Historically, Medical Ikkou Group Co's own Debt-to-EBITDA has ranged from 3.49 to 5.34 over the past decade. While the company's 10-year median is 4.42 vs. the industry median of 2.71, Medical Ikkou Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Conglomerates company?
The median Debt-to-EBITDA among Conglomerates companies is 2.71, based on 453 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Ikkou Group Co's current Debt-to-EBITDA of 3.49 is 28.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medical Ikkou Group Co. For the Conglomerates industry, the median Debt-to-EBITDA is 2.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Ikkou Group Co's current Debt-to-EBITDA is 3.49, which is 21% below median its own 10-year median of 4.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Ikkou Group Co stock overvalued right now?
Based on GuruFocus' analysis, Medical Ikkou Group Co (TSE:3353) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,589.36, compared to a current price of 円2,858.00 — trading 20.4% below its estimated fair value. The current Debt-to-EBITDA is 3.49, which is 21% below median its 10-year median of 4.42 and 28.8% above the Conglomerates industry median of 2.71. Medical Ikkou Group Co's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medical Ikkou Group Co (TSE:3353), the current Debt-to-EBITDA is 3.49 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Ikkou Group Co (TSE:3353) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Ikkou Group Co stock appears to be undervalued.
The current stock price of 円2,858.00 is trading 20.4% below its estimated GF Value™ of 円3,589.36.
GuruFocus considers Medical Ikkou Group Co to be Modestly Undervalued.
Key valuation signals for TSE:3353:
Debt-to-EBITDA: 3.49 (21% below median its 10-year median of 4.42)
GF Value™: 円3,589.36 vs. price of 円2,858.00 (20.4% below fair value)
Industry Position: 28.8% above the Conglomerates median (#272 of 453)
No single metric tells the full story. See the TSE:3353 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Ikkou Group Co Ltd is engaged in Dispensing pharmacy business, healthcare business, pharmaceutical wholesale business, real estate business, and investment business.
64GF Score
Get the complete analysis for TSE:3353
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3353 has been successfully added to your 
